Common Contracts
3 similar Licence Agreement contracts by Nuvectis Pharma, Inc.
LICENCE AGREEMENT between THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH and NUVECTIS PHARMA, INC. University of Edinburgh Legal Services Old College South Bridge Edinburgh, EH8 9YL Ref: [***]Licence Agreement • October 21st, 2021 • Nuvectis Pharma, Inc. • Pharmaceutical preparations
Acquisition Event means (A) the acquisition by any person or entity who or which, together with all associates of such person or entity, shall become the beneficial owner of fifty percent (50%) or more of Nuvectis’s common stock then outstanding, through an unsolicited tender offer or exchange offer or other acquisition of such number of shares by such person, or (B) a change in the majority of the board of directors, whether by resignation or removal, which change occurs as a result of the acquisition of a Controlling interest in the outstanding voting stock of Nuvectis by any person or entity; (C) a merger, consolidation, or reorganisation between Nuvectis and another entity with Nuvectis being either the surviving entity or the acquired entity, or the transfer of assets into Nuvectis for fifty percent (50%) or more of Nuvectis’s equity securities or securities exercisable or convertible into Nuvectis’s equity securities by any person or entity; (D) any sale, lease, assignment, trans
LICENCE AGREEMENT between THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH and NUVECTIS PHARMA, INC. University of Edinburgh Legal Services Old College South Bridge Edinburgh, EH8 9YL Ref: [***]Licence Agreement • October 6th, 2021 • Nuvectis Pharma, Inc. • Pharmaceutical preparations
Acquisition Event means (A) the acquisition by any person or entity who or which, together with all associates of such person or entity, shall become the beneficial owner of fifty percent (50%) or more of Nuvectis’s common stock then outstanding, through an unsolicited tender offer or exchange offer or other acquisition of such number of shares by such person, or (B) a change in the majority of the board of directors, whether by resignation or removal, which change occurs as a result of the acquisition of a Controlling interest in the outstanding voting stock of Nuvectis by any person or entity; (C) a merger, consolidation, or reorganisation between Nuvectis and another entity with Nuvectis being either the surviving entity or the acquired entity, or the transfer of assets into Nuvectis for fifty percent (50%) or more of Nuvectis’s equity securities or securities exercisable or convertible into Nuvectis’s equity securities by any person or entity; (D) any sale, lease, assignment, trans
ContractLicence Agreement • September 20th, 2021 • Nuvectis Pharma, Inc. • Pharmaceutical preparations
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].”
